Literature DB >> 25132354

Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice.

Raul Lazaro1, Raymond Wu, Sunyoung Lee, Nian-Ling Zhu, Chia-Lin Chen, Samuel W French, Jun Xu, Keigo Machida, Hidekazu Tsukamoto.   

Abstract

UNLABELLED: Alcoholic hepatitis (AH) is a distinct spectrum of alcoholic liver disease (ALD) with intense neutrophilic (polymorphonuclear; PMN) inflammation and high mortality. Although a recent study implicates osteopontin (SPP1) in AH, SPP1 is also shown to have protective effects on experimental ALD. To address this unsettled question, we examined the effects of SPP1 deficiency in male mice given 40% calories derived from ad libitum consumption of the Western diet high in cholesterol and saturated fat and the rest from intragastric feeding of alcohol diet without or with weekly alcohol binge. Weekly binge in this new hybrid feeding model shifts chronic ASH with macrophage inflammation and perisinusoidal and pericellular fibrosis to AH in 57% (15 of 26) of mice, accompanied by inductions of chemokines (Spp1, Cxcl1, and interleukin [Il]-17a), progenitor genes (Cd133, Cd24, Nanog, and epithelial cell adhesion molecule), PMN infiltration, and clinical features of AH, such as hypoalbuminemia, bilirubinemia, and splenomegaly. SPP1 deficiency does not reduce AH incidence and inductions of progenitor and fibrogenic genes, but rather enhances the Il-17a induction and PMN infiltration in some mice. Furthermore, in the absence of SPP1, chronic ASH mice without weekly binge begin to develop AH.
CONCLUSION: These results suggest that SPP1 has a protective, rather than causal, role for experimental AH reproduced in our model.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25132354      PMCID: PMC4280361          DOI: 10.1002/hep.27383

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  42 in total

Review 1.  Acute alcoholic hepatitis.

Authors:  Mauro Ceccanti; Adolfo Attili; Giuseppe Balducci; Fabio Attilia; Stefano Giacomelli; Claudia Rotondo; Guido Francesco Sasso; Elias Xirouchakis; Maria Luisa Attilia
Journal:  J Clin Gastroenterol       Date:  2006-10       Impact factor: 3.062

2.  Role of osteopontin in hepatic neutrophil infiltration during alcoholic steatohepatitis.

Authors:  Udayan M Apte; Atrayee Banerjee; Rachel McRee; Elizabeth Wellberg; Shashi K Ramaiah
Journal:  Toxicol Appl Pharmacol       Date:  2005-08-22       Impact factor: 4.219

3.  Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice.

Authors:  Fanli Meng; Kai Wang; Tomonori Aoyama; Sergei I Grivennikov; YongHan Paik; David Scholten; Min Cong; Keiko Iwaisako; Xiao Liu; Mingjun Zhang; Christoph H Österreicher; Felix Stickel; Klaus Ley; David A Brenner; Tatiana Kisseleva
Journal:  Gastroenterology       Date:  2012-06-08       Impact factor: 22.682

4.  Excess weight risk factor for alcoholic liver disease.

Authors:  S Naveau; V Giraud; E Borotto; A Aubert; F Capron; J C Chaput
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

5.  Higher neutrophil infiltration mediated by osteopontin is a likely contributing factor to the increased susceptibility of females to alcoholic liver disease.

Authors:  A Banerjee; U M Apte; R Smith; S K Ramaiah
Journal:  J Pathol       Date:  2006-03       Impact factor: 7.996

6.  Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

Authors:  T Poynard; P Bedossa; P Opolon
Journal:  Lancet       Date:  1997-03-22       Impact factor: 79.321

Review 7.  Mechanisms of synergy between alcohol and hepatitis C virus.

Authors:  Ashwani K Singal; Bhupinder S Anand
Journal:  J Clin Gastroenterol       Date:  2007-09       Impact factor: 3.062

8.  Role of osteopontin in neutrophil function.

Authors:  Adeline Koh; Andre Paes Batista da Silva; Anil K Bansal; Manju Bansal; Chunxiang Sun; Hyejin Lee; Michael Glogauer; Jaro Sodek; Ron Zohar
Journal:  Immunology       Date:  2007-08-03       Impact factor: 7.397

Review 9.  Determinants of alcohol use and abuse: Impact of quantity and frequency patterns on liver disease.

Authors:  Samir Zakhari; Ting-Kai Li
Journal:  Hepatology       Date:  2007-12       Impact factor: 17.425

10.  Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis.

Authors:  Tatiana Kisseleva; Min Cong; Yonghan Paik; David Scholten; Chunyan Jiang; Chris Benner; Keiko Iwaisako; Thomas Moore-Morris; Brian Scott; Hidekazu Tsukamoto; Sylvia M Evans; Wolfgang Dillmann; Christopher K Glass; David A Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-07       Impact factor: 11.205

View more
  59 in total

1.  Comprehensive characterization of hepatocyte-derived extracellular vesicles identifies direct miRNA-based regulation of hepatic stellate cells and DAMP-based hepatic macrophage IL-1β and IL-17 upregulation in alcoholic hepatitis mice.

Authors:  Akiko Eguchi; Rui Yan; Stephanie Q Pan; Raymond Wu; Jihoon Kim; Yibu Chen; Charles Ansong; Richard D Smith; Mina Tempaku; Lucila Ohno-Machado; Yoshiyuki Takei; Ariel E Feldstein; Hidekazu Tsukamoto
Journal:  J Mol Med (Berl)       Date:  2020-06-18       Impact factor: 4.599

2.  Invariant natural killer T cells contribute to chronic-plus-binge ethanol-mediated liver injury by promoting hepatic neutrophil infiltration.

Authors:  Stephanie Mathews; Dechun Feng; Igor Maricic; Cynthia Ju; Vipin Kumar; Bin Gao
Journal:  Cell Mol Immunol       Date:  2015-02-09       Impact factor: 11.530

3.  Gaps in Knowledge and Research Priorities for Alcoholic Hepatitis.

Authors:  Arun J Sanyal; Bin Gao; Gyongyi Szabo
Journal:  Gastroenterology       Date:  2015-05-23       Impact factor: 22.682

Review 4.  Inflammatory pathways in alcoholic steatohepatitis.

Authors:  Bin Gao; Maleeha F Ahmad; Laura E Nagy; Hidekazu Tsukamoto
Journal:  J Hepatol       Date:  2019-02       Impact factor: 25.083

Review 5.  Summary of the 2018 Alcohol and Immunology Research Interest Group (AIRIG) meeting.

Authors:  Paulius V Kuprys; Hidekazu Tsukamoto; Bin Gao; Lin Jia; Jacob McGowan; Craig M Coopersmith; Maria Camargo Moreno; Holly Hulsebus; Avtar S Meena; Flavia M Souza-Smith; Philip Roper; Michelle T Foster; S Vamsee Raju; S Alex Marshall; Mayumi Fujita; Brenda J Curtis; Todd A Wyatt; Pranoti Mandrekar; Elizabeth J Kovacs; Mashkoor A Choudhry
Journal:  Alcohol       Date:  2018-08-24       Impact factor: 2.405

6.  Chronic high-dosage fish oil exacerbates gut-liver axis injury in alcoholic steatohepatitis in mice: the roles of endotoxin and IL-4 in Kupffer cell polarization imbalance.

Authors:  Xiao-Jun Li; Yun-Mei Mu; Qiu-Fang Qin; Zi-Xuan Zeng; Yu-Sang Li; Wei Kevin Zhang; He-Bin Tang; Gui-Hua Tian; Hong-Cai Shang
Journal:  Toxicol Res (Camb)       Date:  2017-07-07       Impact factor: 3.524

Review 7.  Targeting Nrf-2 is a promising intervention approach for the prevention of ethanol-induced liver disease.

Authors:  Ning Zhao; Fang-Fang Guo; Ke-Qin Xie; Tao Zeng
Journal:  Cell Mol Life Sci       Date:  2018-06-11       Impact factor: 9.261

8.  Development of Capsular Fibrosis Beneath the Liver Surface in Humans and Mice.

Authors:  Steven Balog; Yuchang Li; Tomohiro Ogawa; Toshio Miki; Takeshi Saito; Samuel W French; Kinji Asahina
Journal:  Hepatology       Date:  2019-08-27       Impact factor: 17.425

9.  Mitochondrial DNA-enriched microparticles promote acute-on-chronic alcoholic neutrophilia and hepatotoxicity.

Authors:  Yan Cai; Ming-Jiang Xu; Erik H Koritzinsky; Zhou Zhou; Wei Wang; Haixia Cao; Peter St Yuen; Ruth A Ross; Robert A Star; Suthat Liangpunsakul; Bin Gao
Journal:  JCI Insight       Date:  2017-07-20

10.  P2X7 Receptor Antagonist A804598 Inhibits Inflammation in Brain and Liver in C57BL/6J Mice Exposed to Chronic Ethanol and High Fat Diet.

Authors:  Daniel Freire; Rachel E Reyes; Ared Baghram; Daryl L Davies; Liana Asatryan
Journal:  J Neuroimmune Pharmacol       Date:  2018-10-23       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.